Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Liothyronine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 14/20 | 1.00 |
| ▸ | THRA known ✓ | P10827 | 10/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | PCNA | P12004 | 4/20 | 1.00 |
| ▸ | PPARG | P37231 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 2/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 2/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | GABRP | O00591 | 1/20 | 1.00 |
| ▸ | GABRD | O14764 | 1/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 1/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 1/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Detrothyronine SCHEMBL29651848 | 1.00 | THRB (1.00) | THRBTHRALMNAMEN1KMT2A | |
| Detrothyronine SCHEMBL29383803 | 1.00 | THRB (1.00) | THRBTHRALMNAMEN1KMT2A | |
| Liothyronine SCHEMBL3287278 | 1.00 | THRB (1.00) | THRBTHRALMNAMEN1KMT2A | |
| Rathyronine SCHEMBL123365 | 1.00 | THRB (1.00) | THRBTHRALMNAMEN1KMT2A | |
| Liothyronine SCHEMBL8300 | 1.00 | THRB (1.00) | THRBTHRALMNAMEN1KMT2A | |
| Detrothyronine SCHEMBL8301 | 1.00 | THRB (1.00) | THRBTHRALMNAMEN1KMT2A | |
| Detrothyronine SCHEMBL4608153 | 0.99 | THRB (0.97) | THRBTHRALMNAMEN1KMT2A | |
| Liothyronine SCHEMBL2679283 | 0.99 | THRB (0.97) | THRBTHRALMNAMEN1KMT2A | |
| Detrothyronine SCHEMBL21749451 | 0.99 | THRB (0.97) | THRBTHRALMNAMEN1KMT2A | |
| Liothyronine SCHEMBL438744 | 0.99 | THRB (0.97) | THRBTHRALMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4134100-A1 | TREATMENT OF RESISTANT DEPRESSION VIA APPLICATION OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION WITH THYROID HORMONE TREATMENT | The London Psychiatry Centre (GB) | 2023-02-15 | — | — | EP | claimed |
| US-12488870-B2 | Systems and methods for automatically predicting incorrect drug dispensed events in a pharmacy | WALMART APOLLO, LLC (US) | 2025-12-02 | — | — | US | disclosed |
| EP-3148662-B1 | EXTRACTION, DERIVATIZATION, AND QUANTIFICATION OF ANALYTES | TECAN SP INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12403104-B2 | Compounds and methods of promoting myelination | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250127900-A1 | STABLE PHARMACEUTICAL COMPOSITIONS | MANKIND PHARMA LTD. (IN) | 2025-04-24 | — | — | US | disclosed |
| CN-119523873-A | Recombinant nucleic acids encoding one or more cosmetic proteins for cosmetic applications | 克里斯托生物技术股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119499162-A | Recombinant nucleic acids encoding one or more cosmetic proteins for cosmetic applications | 克里斯托生物技术股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20230307111-A1 | SYSTEMS AND METHODS FOR AUTOMATICALLY PREDICTING INCORRECT DRUG DISPENSED EVENTS IN A PHARMACY | WALMART APOLLO, LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230218916-A1 | TREATMENT OF PSYCHIATRIC CONDITIONS SUCH AS RESISTANT DEPRESSION, BIPOLAR DISORDER AND/OR MAJOR DEPRESSIVE DISORDER VIA APPLICATION OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION WITH THYROID HORMONE TREATMENT AND/OR QUETIAPINE | THE LONDON PSYCHIATRY CENTRE (GB) | 2023-07-13 | — | — | US | disclosed |
| WO-2023119100-A1 | STABLE PHARMACEUTICAL COMPOSITIONS | MANKIND PHARMA LTD. (IN) | 2023-06-29 | — | — | WO | disclosed |
| EP-3278100-B1 | METHODS AND USES COMPRISING SOLID PHASE EXTRACTION, DERIVATIZATION WITH CROWN ETHERS, AND MASS SPECTROMETRY | TECAN SP INC (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4134100-A1 | TREATMENT OF RESISTANT DEPRESSION VIA APPLICATION OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION WITH THYROID HORMONE TREATMENT | The London Psychiatry Centre (GB) | 2023-02-15 | — | — | EP | disclosed |
| US-20230000798-A1 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | CASE WESTERN RESERVE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| CN-107530396-B | Adiponectin peptidomimetics for the treatment of ophthalmic diseases | 雅利斯塔制药公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-114652735-A | Compounds and methods for promoting myelination | 凯斯西储大学 | 2022-06-24 | — | — | CN | disclosed |
| US-11344511-B2 | Compounds and methods of promoting myelination | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-05-31 | — | — | US | disclosed |
| CN-114555083-A | Use of orexin 2 receptor agonists for the treatment of excessive sleepiness | 武田药品工业株式会社 | 2022-05-27 | — | — | CN | disclosed |
| CN-114042171-A | Bacterial imaging agents and methods of use thereof | 文森医学公司 | 2022-02-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12403104-B2 | Compounds and methods of promoting myelination | GMFG, MAG, SGMS1 | THRB 2253/4885THRA 3507/4885LMNA 821/4885 |
| US-11344511-B2 | Compounds and methods of promoting myelination | GMFG, MAG, SGMS1 | THRB 2253/4885THRA 3507/4885LMNA 821/4885 |
| US-20230000798-A1 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | GMFG, MAG, SGMS1 | THRB 2253/4885THRA 3507/4885LMNA 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.